Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus

Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to inactivation by human blood components, potentially enabling intravenous dosing in patients with metastatic canc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Ther Oncolytics
Autori principali: Illingworth, Sam, Di, Ying, Bauzon, Maxine, Lei, Janet, Duffy, Margaret R., Alvis, Simon, Champion, Brian, Lieber, André, Hermiston, Terry, Seymour, Len W., Beadle, John, Fisher, Kerry
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Gene & Cell Therapy 2017
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5415321/
https://ncbi.nlm.nih.gov/pubmed/28480328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2017.03.003
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi